Confirmed Control Closed Deal verified Antifungal TreatmentsConsumerConsumer Healthcare / OTC PharmaceuticalsDermatologyOTC Medicines
Lamisil acquired by Karo Healthcare
Karo Healthcare acquired Lamisil, a consumer healthcare / otc pharmaceuticals brand on Aug 1, 2023. Financial terms were not publicly disclosed. The current comp implies EV / revenue of 4.1x. Public sources confirm the deal; valuation inputs may include estimates where transaction materials do not disclose the full economics.
Transaction summary
- Target
- Lamisil
- Acquirer
- Karo Healthcare
- Seller
- Haleon
- Announced
- 2023-08-01
- Geography
- -
- Tags
- Antifungal TreatmentsConsumerConsumer Healthcare / OTC PharmaceuticalsDermatologyOTC Medicines
- Type
- Acquisition
- Deal type
- Control
- Stake acquired
- -
- First added
- 2026-06-19
- Latest update
- 2026-06-19
Value and multiples
Price / value
Undisclosed
-
Basis: FundComb estimate
EV / revenue
4.1x
unknown
Basis: FundComb estimate
EV / EBITDA
-
Basis: FundComb estimate
Basis
- Financial terms were not disclosed in the public sources reviewed.
- EV / revenue is shown as 4.1x based on the available comp inputs.
- Revenue and multiple inputs are not fully disclosed in public transaction materials reviewed; treat the multiple as an estimate.
Source summary
No public source summary has been published for this transaction yet.